To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
13 Current news of Cytheris
rss
Cytheris announces US Orphan Drug Designation for CYT107 for Progressive Multifocal Leucoencephalopathy
26-10-2012
Cytheris SA announced that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation for Cytheris’ CYT017, glycosylated recombinant human interleukin-7 (glycosylated r-h-IL7), for the treatment of Progressive Multifocal Leukoencephalopathy (PML). This designation from ...
Cytheris announces CYT107 orphan drug designation in Europe for the treatment of Progressive Multifocal Leucoencephalopathy (PML)
12-07-2012
Cytheris SA announced that the European Commission has granted an orphan designation for Cytheris' CYT017, glycosylated recombinant human interleukin-7 (glycosylated r-h-IL7), for the treatment of Progressive Multifocal Leukoencephalopathy (PML).Additionally, Cytheris obtained scientific ...
Cytheris appoints Damian Marron as chief executive officer
14-06-2012
Cytheris SA announced the appointment of Damian Marron as chief executive officer. Damian was previously CEO at Trophos SA. Damian Marron, 49, is a highly experienced executive with strong experience in orphan diseases. He was previously CEO of Trophos SA from June 2008. Damian has extensive ...
Cytheris announces results of phase II study indicating that recombinant Interleukin-7 (CYT107) expands CD4 T-cells in gut mucosa of chronically HIV infected immunological non-responder patients
12-03-2012
Cytheris SA announced results of a multi-center phase II study designed to investigate the potential of recombinant human Interleukin-7 (r-hIL-7, CYT107) therapy to reconstitute CD4 T-cells in chronically HIV-1 infected patients whose CD4 T-cell counts remained low despite treatment with ...
Cytheris and Cancer Immunotherapy Trials Network (CITN) announce selection of recombinant interleukin-7 (CYT107) for initial studies at member institutions
18-05-2011
Cytheris SA and the Cancer Immunotherapy Trials Network (CITN), a new initiative in immunotherapy funded by the National Cancer Institute with its Central Operations and Statistical Center (COSC), announced the selection of recombinant human interleukin-7 (CYT107), the investigational ...
Cytheris, Centre Léon Bérard and ImmunID announce initiation of clinical trial to evaluate combination regimen of IL-7 (CYT107) and XELODA (R) (capecitabine) in treatment of metastatic breast cancer
13-05-2011
Cytheris SA, the Centre Léon Bérard and ImmunID Technologies SAS announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7 (CYT107), the investigational multifunctional cytokine under development by Cytheris, and a ...
Cytheris announces results of phase IIa study indicating that recombinant interleukin-7 (CYT107) expands CD4 T-Cells in gut mucosa of chronically HIV infected immunological non-responder patients
03-03-2011
Cytheris SA announced results of a multi-center Phase IIa study designed to investigate the potential of Interleukin-7 (CYT107) therapy to reconstitute CD4 T-cells in chronically HIV-1 infected patients whose CD4 T-cell counts remained low despite treatment with anti-retroviral-therapies ...
Cytheris announces publication of clinical case study combining recombinant human interleukin-7 with antiviral agent CMX001
Combination therapy with two investigational agents, Cytheris’ CYT107 and Chimerix’s CMX001, indicates potential for clearing the JC virus that causes PML, a rare and usually fatal neurological disease
06-12-2010
Cytheris SA announced the publication of a case study report based on successful treatment of progressive multifocal leukoencephalopathy (PML) with combination therapy consisting of two investigational agents, Cytheris’ recombinant human interleukin-7 (CYT107) and CMX001, an investigational, ...
ORVACS Phase II clinical study attacks the viral reservoir of HIV patients
10-11-2010
ORVACS (Objectif Recherche VACcin Sida) has launched a Phase II study designed to test the hypotheses that combination therapy with potent antiviral agents and immunomodulator can lead to a decrease in the HIV viral reservoirs and, ultimately, to eradication of the virus. The study is ...
Cytheris initiates INSPIRE 3 trial of recombinant human interleukin-7 (CYT107) in chronically infected HIV patients
23-09-2010
Cytheris SA announced that it has begun enrolling patients in INSPIRE 3, a Phase II clinical program evaluating the effect of repeated cycles of the company’s investigative immune-modulator, recombinant human interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients ...
Netmeeting
